Tokyo, Japan – 27 September 2011: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri® Breezhaler®, triggering a $5m milestone payment to Sosei.